Register to view the archived recording here.
Goldman Sachs Lowers Estimates on Illumina, But Favors MiSeq Growth Over PGM
The investment firm lowered EPS estimates for Illumina on an expected shift to the MiSeq platform from the HiSeq system, but said that in a short amount of time Illumina's desktop sequencer would overtake Ion Torrent's PGM as the market leader.
New to GenomeWeb? Register here quickly for free access.